Overactive bladder-18 years - Part II

Overactive bladder-18 years - Part II

Author Truzzi, Jose Carlos Autor UNIFESP Google Scholar
Gomes, Cristiano Mendes Google Scholar
Bezerra, Carlos A. Google Scholar
Plata, Ivan Mauricio Google Scholar
Campos, Jose Google Scholar
Garrido, Gustavo Luis Google Scholar
Almeida, Fernando G. Autor UNIFESP Google Scholar
Averbeck, Marcio Augusto Google Scholar
Fornari, Alexandre Google Scholar
Salazar, Anibal Google Scholar
Dell'Oro, Arturo Google Scholar
Cintra, Caio Google Scholar
Ricetto Sacomani, Carlos Alberto Google Scholar
Tapia, Juan Pablo Google Scholar
Brambila, Eduardo Google Scholar
Longo, Emilio Miguel Google Scholar
Rocha, Flavio Trigo Google Scholar
Coutinho, Francisco Google Scholar
Favre, Gabriel Google Scholar
Garcia, Jose Antonio Google Scholar
Castano, Juan Google Scholar
Reyes, Miguel Google Scholar
Leyton, Rodrigo Eugenio Google Scholar
Ferreira, Ruiter Silva Google Scholar
Duran, Sergio Google Scholar
Lopez, Vanda Google Scholar
Reges, Ricardo Google Scholar
Abstract Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics - pillars of the overactive bladder pharmacotherapy - started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning - as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder - 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder.
Keywords Overactive Bladder
Muscarinic Antagonists
Beta-adrenergic agonists
Botulinum Toxin
Sacral neuromodulation
xmlui.dri2xhtml.METS-1.0.item-coverage Rio De Janeiro
Language English
Date 2016
Published in International Braz J Urol. Rio De Janeiro, v. 42, n. 2, p. 199-214, 2016.
ISSN 1677-5538 (Sherpa/Romeo, impact factor)
Publisher Brazilian Soc Urol
Extent 199-214
Origin http://dx.doi.org/10.1590/S1677-5538.IBJU.2015.0367
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000375604900006
SciELO ID S1677-55382016000200199 (statistics in SciELO)
URI https://repositorio.unifesp.br/handle/11600/57829

Show full item record


Name: S1677-55382016000200199-en.pdf
Size: 203.9Kb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account